Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Vaxcyte, Inc.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

James Wood Johnson

Edward Mead Johnson

Robert Wood Johnson

Johnson & Johnson

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Bror Morein

Novavax, Inc.

Vaxcyte is a clinical-stage vaccine innovation company developing high-fidelity vaccines to prevent bacterial diseases, with a focus on pneumococcal vaccines.

Metric
Company Name	Vaxcyte, Inc.	Johnson & Johnson	Novavax, Inc.
Symbol	PCVX	JNJ	NVAX
MSH ID	COM:VAXCYTE	COM:JNJ	COM:NOVAVAX
Market	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Drug Manufacturers - General	Biotechnology
Country	US	US	US
Stage
Employee Count	254	131.90K	1.54K
Website	vaxcyte.com	jnj.com	novavax.com
LinkedIn		johnson-&-johnson	novavax
Founders

Metric
Market Cap	8.81B	359.63B	1.68B
Enterprise Value
Monthly Web Traffic		2.26M
Web Traffic Growth		0.02
Valuation
Raised Capital

Metric
Revenue	85.15B	983.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	58.41B	704.24M
EBITDA	29.34B	-373.80M
Operating Income	21.85B	-415.03M
Net Income	14.17B	-545.06M
EPS	5.59	-5.41
Diluted EPS	5.53	-5.41
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.71	0.60
Operating Profit Margin	0.30	-0.35
EBITDA Margin	0.34	-0.38
Net Profit Margin	0.45	-0.36
Return on Equity	0.57	0.72
Return on Assets	0.24	-0.16
Return on Capital Employed	0.21	-0.43

COM:VAXCYTE

Vaxcyte

Last Close

88.39

22/11 21:00

Market Cap

8.81B

Beta: -

Volume Today

1.61M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	10.85	-0.70
P/B Ratio	5.27	-0.56
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.66	3.54
EV Multiple	13.83	-1.84

Metric
Days Sales Outstanding	56.66	55.36
Days Payables Outstanding	98.44	100.39
Days Inventory Outstanding	178.66	45.07
Operating Cycle	245.26	177.58
Cash Conversion Cycle	115.35	34.23
Asset Turnover	0.56	0.61

Metric
Operating Cash Flow	22.79B	-717.56M
Free Cash Flow	18.25B	-776.36M
Cash Flow to Debt	0.78	0.08
Operating Cash Flow/Sales	0.28	0.02
Free Cash Flow Yield	0.04	-1.65

Metric
Cash & Equivalents	21.86B	578.93M
Accounts Receivable	-624M	-274.44M
Inventory	11.18B	41.70M
Goodwill	36.56B	127.45M
Debt to Capitalization	0.37	-0.25
Debt to Assets	0.18	0.13
Current Ratio	1.21	0.69
Quick Ratio	0.94	1.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.12
R&D to Revenue	0.16	1.02
SG&A to Revenue	0.06